ClinicalTrials.gg
CompletedNCT00860262Updated May 20, 2014Results posted

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

A Phase 3 interventional study of amlodipine and telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed at 137 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
858
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
14th of 99
858 · median 184
Started
2009
with 3 others
Phase 3
40 of 99
none open now
Registered
36th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 14th largest by enrollment, is one of 4 that started in 2009, is one of 40 in phase 3, and was the 36th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The primary objective of this trial is to demonstrate that following eight weeks of treatment the FDC of telmisartan 80 mg plus amlodipine 10 mg (T80/A10) is superior as first line therapy in reducing mean seated trough cuff Systolic Blood Pressure [SBP] compared to the monotherapies of telmisartan 80 mg (T80) and amlodipine 10 mg (A10) in patients with severe hypertension. A key secondary objective is to identify the duration of treatment required to demonstrate the superiority of the FDC over both of the monotherapies.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

  1. Ability to provide written in accordance with Good Clinical Practice and local legislation
  2. Age 18 years or older
  3. Patients with severe hypertension as defined SBP greater than 180 mmHg and DBP greater than 95 mmHg at randomisation
  4. Ability to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigators discretion)

Exclusion criteria Mean in-clinic seated cuff SBP >/= 200 mmHg and/or Diastolic Blood Pressure [DBP] >/= 95 mmHg

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
858 participants (actual)

Study arms

  • Experimental
    telmisartan and amlodipine

    telmisartan and amlodipine used in combination vs amlodipine or telmisartan

    Drug: telmisartan and amlodipine

  • Active comparator
    amlodipine

    telmisartan and amlodipine used in combination vs amlodipine or telmisartan

    Drug: amlodipine

  • Active comparator
    telmisartan

    telmisartan and amlodipine used in combination vs amlodipine or telmisartan

    Drug: telmisartan

Interventions

  • amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w

  • telmisartan 80mg for the 8w, no titration required

  • Drugtelmisartan and amlodipine

    Drug pages: Telmisartan · Amlodipine

    telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8

    Overall mean reduction from a common mean baseline in SBP

    Time frame: baseline and week 8

Secondary outcomes

  1. Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6

    Overall mean reduction from a common mean baseline in SBP

    Time frame: baseline and week 6

  2. Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4

    Overall mean reduction from a common mean baseline in SBP

    Time frame: baseline and week 4

  3. Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2

    Overall mean reduction from a common mean baseline in SBP

    Time frame: baseline and week 2

  4. Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1

    Overall mean reduction from a common mean baseline in SBP

    Time frame: baseline and week 1

  5. Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8

    Overall mean reduction from a common mean baseline in DBP

    Time frame: baseline and week 8

  6. Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6

    Overall mean reduction from a common mean baseline in DBP

    Time frame: baseline and week 6

  7. Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4

    Overall mean reduction from a common mean baseline in DBP

    Time frame: baseline and week 4

  8. Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2

    Overall mean reduction from a common mean baseline in DBP

    Time frame: baseline and week 2

  9. Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1

    Overall mean reduction from a common mean baseline in DBP

    Time frame: baseline and week 1

  10. Patients Achieving Diastolic Blood Pressure Control at Week 1

    Diastolic Blood Pressure Control is defined as achieving DBP \< 90mmHg

    Time frame: week 1

  11. Patients Achieving Diastolic Blood Pressure Control at Week 2

    DBP \< 90 mmHg

    Time frame: week 2

  12. Patients Achieving Blood Pressure Control at Week 1

    Blood Pressure Control is defined as achieving SBP\< 140 mmHg and DBP \< 90mmHg

    Time frame: week 1

  13. Patients Achieving Blood Pressure Control at Week 2

    SBP \< 140 mmHg and DBP \< 90 mmHg

    Time frame: week 2

  14. Patients Achieving Diastolic Blood Pressure Response at Week 1

    Diastolic Blood Pressure Response is defined as achieving DBP \< 90 mmHg or a reduction of \>= 10 mmHg

    Time frame: baseline, week 1

  15. Patients Achieving Diastolic Blood Pressure Response at Week 2

    DBP \< 90 mmHg or reduction of \>= 10 mmHg

    Time frame: baseline, week 2

  16. Patients Achieving Systolic Blood Pressure Response at Week 1

    Systolic Blood Pressure Response Control is defined as achieving SBP \< 140 mmHg or a reduction of \>= 15 mmHg

    Time frame: baseline, week 1

  17. Patients Achieving Systolic Blood Pressure Response at Week 2

    SBP \< 140 mmHg or reduction of \>= 15 mmHg

    Time frame: baseline, week 2

  18. Number of Patients Achieving Various Blood Pressure Response Levels at Week 1

    Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

    Time frame: week 1

  19. Number of Patients Achieving Various Blood Pressure Response Levels at Week 2

    Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

    Time frame: week 2

  20. Patients Achieving Diastolic Blood Pressure Control at Week 4

    DBP \< 90 mmHg

    Time frame: week 4

  21. Patients Achieving Diastolic Blood Pressure Control at Week 6

    DBP \< 90 mmHg

    Time frame: week 6

  22. Patients Achieving Diastolic Blood Pressure Control at Week 8

    DBP \< 90 mmHg

    Time frame: week 8

  23. Patients Achieving Blood Pressure Control at Week 4

    SBP \< 140 mmHg and DBP \< 90 mmHg

    Time frame: week 4

  24. Patients Achieving Blood Pressure Control at Week 6

    SBP \< 140 mmHg and DBP \< 90 mmHg

    Time frame: week 6

  25. Patients Achieving Blood Pressure Control at Week 8

    SBP \< 140 mmHg and DBP \< 90 mmHg

    Time frame: week 8

  26. Patients Achieving Diastolic Blood Pressure Response at Week 4

    DBP \< 90 mmHg or reduction of \>= 10 mmHg

    Time frame: baseline, week 4

  27. Patients Achieving Diastolic Blood Pressure Response at Week 6

    DBP \< 90 mmHg or reduction of \>= 10 mmHg

    Time frame: baseline, week 6

  28. Patients Achieving Diastolic Blood Pressure Response at Week 8

    DBP \< 90 mmHg or reduction of \>= 10 mmHg

    Time frame: baseline, week 8

  29. Patients Achieving Systolic Blood Pressure Response at Week 4

    SBP \< 140 mmHg or reduction of \>= 15 mmHg

    Time frame: baseline, week 4

  30. Patients Achieving Systolic Blood Pressure Response at Week 6

    SBP \< 140 mmHg or reduction of \>= 15 mmHg

    Time frame: baseline, week 6

  31. Patients Achieving Systolic Blood Pressure Response at Week 8

    SBP \< 140 mmHg or reduction of \>= 15 mmHg

    Time frame: baseline, week 8

  32. Patients Achieving Normal Blood Pressure Response at Week 4

    Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

    Time frame: week 4

  33. Patients Achieving Normal Blood Pressure Response at Week 6

    Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

    Time frame: week 6

  34. Patients Achieving Normal Blood Pressure Response at Week 8

    Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

    Time frame: week 8

07

Results

Posted Jan 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneT80+A10Telmisartan 80 mgAmlodipine 10 mg
Started421217220
Completed401195202
Not completed202218
Withdrew: Adverse event967
Withdrew: Protocol violation010
Withdrew: Lost to follow-up201
Withdrew: Withdrawal by subject486
Withdrew: Lack of efficacy043
Withdrew: Other531

Outcome measures

PrimaryChange From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8

Overall mean reduction from a common mean baseline in SBP

Time frame:
baseline and week 8
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8-47.5 ± 0.69-36.9 ± 0.96-43.2 ± 0.95
Statistical analysis
  • T80+A10 vs Telmisartan 80 mg · Repeated measures ANCOVA · p = <0.0001 · Mean difference (final values): -10.6 · 95% CI -12.9 to -8.3Difference calculated as T80+A10 minus Telmisartan 80 mg
  • T80+A10 vs Amlodipine 10 mg · Repeated measures ANCOVA · p = 0.0002 · Mean difference (final values): -4.4 · 95% CI -6.7 to -2.1Difference calculated as T80+A10 minus amlodipine 10 mg
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure at Week 6

Overall mean reduction from a common mean baseline in SBP

Time frame:
baseline and week 6
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6-46.9 ± 0.73-36.3 ± 1.01-42.1 ± 1.01
Statistical analysis
  • T80+A10 vs Telmisartan 80 mg · Repeated measures ANCOVA · p = <0.0001 · Mean difference (final values): -10.6 · 95% CI -13.1 to -8.2Difference calculated as T80+A10 minus telmisartan 80 mg
  • T80+A10 vs Amlodipine 10 mg · Repeated measures ANCOVA · p = 0.0001 · Mean difference (final values): -4.8 · 95% CI -7.3 to -2.4Difference calculated as T80+A10 minus amlodipine 10 mg
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure at Week 4

Overall mean reduction from a common mean baseline in SBP

Time frame:
baseline and week 4
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 4-44.5 ± 0.73-34.4 ± 1.01-39.8 ± 1.01
Statistical analysis
  • T80+A10 vs Telmisartan 80 mg · Repeated measures ANCOVA · p = <0.0001 · Mean difference (final values): -10.2 · 95% CI -12.6 to -7.7Difference calculated as T80+A10 minus telmisartan 80 mg
  • T80+A10 vs Amlodipine 10 mg · Repeated measures ANCOVA · p = 0.0001 · Mean difference (final values): -4.8 · 95% CI -7.2 to -2.4Difference calculated as T80+A10 minus amlodipine 10 mg
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure at Week 2

Overall mean reduction from a common mean baseline in SBP

Time frame:
baseline and week 2
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2
mmHg (millimeters of mercury)T80+A5Telmisartan 80 mgAmlodipine 5 mg
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 2-37.9 ± 0.71-30.1 ± 0.97-33.3 ± 0.98
Statistical analysis
  • T80+A5 vs Telmisartan 80 mg · Repeated measures ANCOVA · p = <0.0001 · Mean difference (final values): -7.8 · 95% CI -10.2 to -5.4Difference calculated as T80+A10 minus telmisartan 80 mg
  • T80+A5 vs Amlodipine 5 mg · Repeated measures ANCOVA · p = 0.0001 · Mean difference (final values): -4.6 · 95% CI -7.0 to -2.3Difference calculated as T80+A10 minus amlodipine 10 mg
SecondaryChange From Baseline in Trough Seated Systolic Blood Pressure at Week 1

Overall mean reduction from a common mean baseline in SBP

Time frame:
baseline and week 1
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1
mmHg (millimeters of mercury)T80+A5Telmisartan 80 mgAmlodipine 5 mg
Change From Baseline in Trough Seated Systolic Blood Pressure at Week 1-31.9 ± 0.72-25.4 ± 0.99-28.6 ± 0.99
Statistical analysis
  • T80+A5 vs Telmisartan 80 mg · Repeated measures ANCOVA · p = <0.0001 · Mean difference (final values): -6.4 · 95% CI -8.8 to -4.0Difference calculated as T80+A10 minus telmisartan 80 mg
  • T80+A5 vs Amlodipine 5 mg · Repeated measures ANCOVA · p = 0.0077 · Mean difference (final values): -3.3 · 95% CI -5.7 to -0.9Difference calculated as T80+A10 minus amlodipine 10 mg
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8

Overall mean reduction from a common mean baseline in DBP

Time frame:
baseline and week 8
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) at Week 8-18.7 ± 0.41-13.8 ± 0.58-16.3 ± 0.58
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure at Week 6

Overall mean reduction from a common mean baseline in DBP

Time frame:
baseline and week 6
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6-18.3 ± 0.41-13.5 ± 0.57-15.7 ± 0.57
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure at Week 4

Overall mean reduction from a common mean baseline in DBP

Time frame:
baseline and week 4
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4
mmHg (millimeters of mercury)T80+A10Telmisartan 80 mgAmlodipine 10 mg
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 4-17.0 ± 0.43-12.1 ± 0.60-14.2 ± 0.60
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure at Week 2

Overall mean reduction from a common mean baseline in DBP

Time frame:
baseline and week 2
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2
mmHg (millimeters of mercury)T80+A5Telmisartan 80 mgAmlodipine 5 mg
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 2-13.2 ± 0.40-10.4 ± 0.56-11.4 ± 0.56
SecondaryChange From Baseline in Trough Seated Diastolic Blood Pressure at Week 1

Overall mean reduction from a common mean baseline in DBP

Time frame:
baseline and week 1
Reported as:
Least squares mean · mmHg (millimeters of mercury)
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1
mmHg (millimeters of mercury)T80+A5Telmisartan 80 mgAmlodipine 5 mg
Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 1-10.9 ± 0.37-8.2 ± 0.50-9.6 ± 0.50
SecondaryPatients Achieving Diastolic Blood Pressure Control at Week 1

Diastolic Blood Pressure Control is defined as achieving DBP \< 90mmHg

Time frame:
week 1
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Control at Week 1
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled1476164
Not Controlled240146143
SecondaryPatients Achieving Diastolic Blood Pressure Control at Week 2

DBP \< 90 mmHg

Time frame:
week 2
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Control at Week 2
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled2058791
Not Controlled200125121
SecondaryPatients Achieving Blood Pressure Control at Week 1

Blood Pressure Control is defined as achieving SBP\< 140 mmHg and DBP \< 90mmHg

Time frame:
week 1
Reported as:
Number · participants
Patients Achieving Blood Pressure Control at Week 1
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled541615
Not Controlled333191192
SecondaryPatients Achieving Blood Pressure Control at Week 2

SBP \< 140 mmHg and DBP \< 90 mmHg

Time frame:
week 2
Reported as:
Number · participants
Patients Achieving Blood Pressure Control at Week 2
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled883028
Not Controlled317182184
SecondaryPatients Achieving Diastolic Blood Pressure Response at Week 1

Diastolic Blood Pressure Response is defined as achieving DBP \< 90 mmHg or a reduction of \>= 10 mmHg

Time frame:
baseline, week 1
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Response at Week 1
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled23295100
Not Controlled155112107
SecondaryPatients Achieving Diastolic Blood Pressure Response at Week 2

DBP \< 90 mmHg or reduction of \>= 10 mmHg

Time frame:
baseline, week 2
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Response at Week 2
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled289123128
Not Controlled1168984
SecondaryPatients Achieving Systolic Blood Pressure Response at Week 1

Systolic Blood Pressure Response Control is defined as achieving SBP \< 140 mmHg or a reduction of \>= 15 mmHg

Time frame:
baseline, week 1
Reported as:
Number · participants
Patients Achieving Systolic Blood Pressure Response at Week 1
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled338164173
Not Controlled494334
SecondaryPatients Achieving Systolic Blood Pressure Response at Week 2

SBP \< 140 mmHg or reduction of \>= 15 mmHg

Time frame:
baseline, week 2
Reported as:
Number · participants
Patients Achieving Systolic Blood Pressure Response at Week 2
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Controlled387169189
Not Controlled184323
SecondaryNumber of Patients Achieving Various Blood Pressure Response Levels at Week 1

Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

Time frame:
week 1
Reported as:
Number · participants
Number of Patients Achieving Various Blood Pressure Response Levels at Week 1
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Optimal300
Normal933
High Normal421312
High333191192
SecondaryNumber of Patients Achieving Various Blood Pressure Response Levels at Week 2

Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

Time frame:
week 2
Reported as:
Number · participants
Number of Patients Achieving Various Blood Pressure Response Levels at Week 2
participantsT80+A5Telmisartan 80 mgAmlodipine 5 mg
Optimal600
Normal2175
High Normal612323
High317182184
SecondaryPatients Achieving Diastolic Blood Pressure Control at Week 4

DBP \< 90 mmHg

Time frame:
week 4
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Control at Week 4
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled268106109
Not Controlled12410694
SecondaryPatients Achieving Diastolic Blood Pressure Control at Week 6

DBP \< 90 mmHg

Time frame:
week 6
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Control at Week 6
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled290110128
Not Controlled10410277
SecondaryPatients Achieving Diastolic Blood Pressure Control at Week 8

DBP \< 90 mmHg

Time frame:
week 8
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Control at Week 8
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled291112131
Not Controlled10310074
SecondaryPatients Achieving Blood Pressure Control at Week 4

SBP \< 140 mmHg and DBP \< 90 mmHg

Time frame:
week 4
Reported as:
Number · participants
Patients Achieving Blood Pressure Control at Week 4
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled1614953
Not Controlled231163150
SecondaryPatients Achieving Blood Pressure Control at Week 6

SBP \< 140 mmHg and DBP \< 90 mmHg

Time frame:
week 6
Reported as:
Number · participants
Patients Achieving Blood Pressure Control at Week 6
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled1965477
Not Controlled198158128
SecondaryPatients Achieving Blood Pressure Control at Week 8

SBP \< 140 mmHg and DBP \< 90 mmHg

Time frame:
week 8
Reported as:
Number · participants
Patients Achieving Blood Pressure Control at Week 8
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled1995173
Not Controlled196161132
SecondaryPatients Achieving Diastolic Blood Pressure Response at Week 4

DBP \< 90 mmHg or reduction of \>= 10 mmHg

Time frame:
baseline, week 4
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Response at Week 4
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled339132151
Not Controlled538061
SecondaryPatients Achieving Diastolic Blood Pressure Response at Week 6

DBP \< 90 mmHg or reduction of \>= 10 mmHg

Time frame:
baseline, week 6
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Response at Week 6
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled356144168
Not Controlled386837
SecondaryPatients Achieving Diastolic Blood Pressure Response at Week 8

DBP \< 90 mmHg or reduction of \>= 10 mmHg

Time frame:
baseline, week 8
Reported as:
Number · participants
Patients Achieving Diastolic Blood Pressure Response at Week 8
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled361147172
Not Controlled346533
SecondaryPatients Achieving Systolic Blood Pressure Response at Week 4

SBP \< 140 mmHg or reduction of \>= 15 mmHg

Time frame:
baseline, week 4
Reported as:
Number · participants
Patients Achieving Systolic Blood Pressure Response at Week 4
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled388180194
Not Controlled4329
SecondaryPatients Achieving Systolic Blood Pressure Response at Week 6

SBP \< 140 mmHg or reduction of \>= 15 mmHg

Time frame:
baseline, week 6
Reported as:
Number · participants
Patients Achieving Systolic Blood Pressure Response at Week 6
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled388184201
Not Controlled6284
SecondaryPatients Achieving Systolic Blood Pressure Response at Week 8

SBP \< 140 mmHg or reduction of \>= 15 mmHg

Time frame:
baseline, week 8
Reported as:
Number · participants
Patients Achieving Systolic Blood Pressure Response at Week 8
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Controlled391188202
Not Controlled4243
SecondaryPatients Achieving Normal Blood Pressure Response at Week 4

Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

Time frame:
week 4
Reported as:
Number · participants
Patients Achieving Normal Blood Pressure Response at Week 4
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Optimal1542
Normal471514
High Normal993037
High231163150
SecondaryPatients Achieving Normal Blood Pressure Response at Week 6

Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

Time frame:
week 6
Reported as:
Number · participants
Patients Achieving Normal Blood Pressure Response at Week 6
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Optimal1753
Normal731918
High Normal1063056
High198158128
SecondaryPatients Achieving Normal Blood Pressure Response at Week 8

Optimal: SBP\<120 and DBP\< 80; Normal: 120\<=SBP\<130 and 80\<= DBP\<85; High normal: 130\<=SBP\<140 and 85\<=DBP\<90; High: SBP\>=140 or DBP\>=90

Time frame:
week 8
Reported as:
Number · participants
Patients Achieving Normal Blood Pressure Response at Week 8
participantsT80+A10Telmisartan 80 mgAmlodipine 10 mg
Optimal1832
Normal762125
High Normal1052746
High196161132

Adverse events

Collected over First study medication intake, last study medication intake + 6 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T80+A10—3/421 (0.7%)67/421 (15.9%)
Telmisartan 80 mg—2/217 (0.9%)25/217 (11.5%)
Amlodipine 10 mg—2/220 (0.9%)42/220 (19.1%)
Most frequent serious events
Most frequent serious events
EventT80+A10Telmisartan 80 mgAmlodipine 10 mg
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4211/2170/220
Transient ischaemic attackNervous system disorders0/4211/2170/220
Atrial fibrillationCardiac disorders0/4210/2171/220
Atrioventricular block second degreeCardiac disorders0/4210/2171/220
Diverticular perforationGastrointestinal disorders1/4210/2170/220
Peridiverticular abscessInfections and infestations1/4210/2170/220
Ischaemic strokeNervous system disorders1/4210/2170/220
AsthmaRespiratory, thoracic and mediastinal disorders1/4210/2170/220
Most frequent other events
Most frequent other events
EventT80+A10Telmisartan 80 mgAmlodipine 10 mg
Oedema peripheralGeneral disorders55/4218/21733/220
HeadacheNervous system disorders16/42118/21712/220

Baseline characteristics

Age, Continuous
Age, Continuous(years)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
Mean58.0 ± 10.458.1 ± 10.258.6 ± 10.558.2 ± 10.3
Age, Customized
Age, Customized(Participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
< 65 years309158156623
>= 65 years1125964235
Sex: Female, Male
Sex: Female, Male(Participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
Female202109102413
Male219108118445
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
White362186190738
Black/African American34151564
Asian20141448
American Indian/Alaska Native5106
Hawaiian/Pacific Islander0112
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meter)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
Mean30.6 ± 5.930.2 ± 5.230.7 ± 6.330.6 ± 5.8
Body Mass Index Class
Body Mass Index Class(participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
BMI < 25633135129
25 <= BMI < 301607982321
BMI >= 30198107103408
Race Class
Race Class(participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
Non-Black387202205794
Black34151564
Type II Diabetes
Type II Diabetes(participants)T80+A10Telmisartan 80 mgAmlodipine 10 mgTotal
No349183197729
Yes723423129

3 further baseline measures are reported on the registry.

08

Study locations

137 sites
  • 1235.20.525 Boehringer Ingelheim Investigational Site
    Buena Park, California, United States
  • 1235.20.503 Boehringer Ingelheim Investigational Site
    Long Beach, California, United States
  • 1235.20.507 Boehringer Ingelheim Investigational Site
    Long Beach, California, United States
  • 1235.20.529 Boehringer Ingelheim Investigational Site
    Roseville, California, United States
  • 1235.20.518 Boehringer Ingelheim Investigational Site
    Tustin, California, United States
  • 1235.20.521 Boehringer Ingelheim Investigational Site
    Westlake Village, California, United States
  • 1235.20.508 Boehringer Ingelheim Investigational Site
    DeLand, Florida, United States
  • 1235.20.506 Boehringer Ingelheim Investigational Site
    Hialeah, Florida, United States
  • 1235.20.519 Boehringer Ingelheim Investigational Site
    Pembroke Pines, Florida, United States
  • 1235.20.523 Boehringer Ingelheim Investigational Site
    Port Orange, Florida, United States
  • 1235.20.528 Boehringer Ingelheim Investigational Site
    Blue Ridge, Georgia, United States
  • 1235.20.516 Boehringer Ingelheim Investigational Site
    North Dartmouth, Massachusetts, United States
  • 1235.20.527 Boehringer Ingelheim Investigational Site
    Bay City, Michigan, United States
  • 1235.20.510 Boehringer Ingelheim Investigational Site
    Las Vegas, Nevada, United States
  • 1235.20.512 Boehringer Ingelheim Investigational Site
    Albuquerque, New Mexico, United States
  • 1235.20.509 Boehringer Ingelheim Investigational Site
    Bronx, New York, United States
  • 1235.20.511 Boehringer Ingelheim Investigational Site
    Kettering, Ohio, United States
  • 1235.20.515 Boehringer Ingelheim Investigational Site
    Tulsa, Oklahoma, United States
  • 1235.20.534 Boehringer Ingelheim Investigational Site
    Medford, Oregon, United States
  • 1235.20.526 Boehringer Ingelheim Investigational Site
    Erie, Pennsylvania, United States
  • 1235.20.513 Boehringer Ingelheim Investigational Site
    Tipton, Pennsylvania, United States
  • 1235.20.517 Boehringer Ingelheim Investigational Site
    Providence, Rhode Island, United States
  • 1235.20.522 Boehringer Ingelheim Investigational Site
    Carrollton, Texas, United States
  • 1235.20.520 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1235.20.530 Boehringer Ingelheim Investigational Site
    Killeen, Texas, United States
  • 1235.20.535 Boehringer Ingelheim Investigational Site
    Draper, Utah, United States
  • 1235.20.533 Boehringer Ingelheim Investigational Site
    Magna, Utah, United States
  • 1235.20.505 Boehringer Ingelheim Investigational Site
    Saratoga Springs, Utah, United States
  • 1235.20.537 Boehringer Ingelheim Investigational Site
    Tacoma, Washington, United States
  • 1235.20.501 Boehringer Ingelheim Investigational Site
    Madison, Wisconsin, United States
  • 1235.20.001 Boehringer Ingelheim Investigational Site
    Bourgas, Bulgaria
  • 1235.20.002 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.003 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.005 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.006 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.007 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.008 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.009 Boehringer Ingelheim Investigational Site
    Sofia, Bulgaria
  • 1235.20.004 Boehringer Ingelheim Investigational Site
    Stara Zagora, Bulgaria
  • 1235.20.052 Boehringer Ingelheim Investigational Site
    Benatky nad Jizerou, Czech Republic
  • 1235.20.059 Boehringer Ingelheim Investigational Site
    Cesky Krumlov, Czech Republic
  • 1235.20.051 Boehringer Ingelheim Investigational Site
    Plzen, Czech Republic
  • 1235.20.053 Boehringer Ingelheim Investigational Site
    Praha 5, Czech Republic
  • 1235.20.054 Boehringer Ingelheim Investigational Site
    Pribram, Czech Republic
  • 1235.20.055 Boehringer Ingelheim Investigational Site
    Slany, Czech Republic
  • 1235.20.057 Boehringer Ingelheim Investigational Site
    Strakonice, Czech Republic
  • 1235.20.058 Boehringer Ingelheim Investigational Site
    Tabor, Czech Republic
  • 1235.20.101A Boehringer Ingelheim Investigational Site
    Albens, France
  • 1235.20.102F Boehringer Ingelheim Investigational Site
    Arles, France
  • 1235.20.103A Boehringer Ingelheim Investigational Site
    Beziers, France
  • 1235.20.103C Boehringer Ingelheim Investigational Site
    Beziers, France
  • 1235.20.103F Boehringer Ingelheim Investigational Site
    Beziers, France
  • 1235.20.106A Boehringer Ingelheim Investigational Site
    Bourg des cptes, France
  • 1235.20.109B Boehringer Ingelheim Investigational Site
    Brive, France
  • 1235.20.108E Boehringer Ingelheim Investigational Site
    Carbonne, France
  • 1235.20.101D Boehringer Ingelheim Investigational Site
    Chambery, France
  • 1235.20.103E Boehringer Ingelheim Investigational Site
    Cournonterral, France
  • 1235.20.108C Boehringer Ingelheim Investigational Site
    Cugnaux, France
  • 1235.20.106D Boehringer Ingelheim Investigational Site
    Etrelles, France
  • 1235.20.108F Boehringer Ingelheim Investigational Site
    Fenouillet, France
  • 1235.20.102A Boehringer Ingelheim Investigational Site
    Gemenos, France
  • 1235.20.102C Boehringer Ingelheim Investigational Site
    Gemenos, France
  • 1235.20.101C Boehringer Ingelheim Investigational Site
    Gresy Sur Aix, France
  • 1235.20.108A Boehringer Ingelheim Investigational Site
    Labarthe Sur Leze, France
  • 1235.20.108B Boehringer Ingelheim Investigational Site
    Labarthe sur Leze, France
  • 1235.20.106F Boehringer Ingelheim Investigational Site
    Louvigne De bais, France
  • 1235.20.102E Boehringer Ingelheim Investigational Site
    Marseille, France
  • 1235.20.106B Boehringer Ingelheim Investigational Site
    Mordelles, France
  • 1235.20.107A Boehringer Ingelheim Investigational Site
    Ortez, France
  • 1235.20.107B Boehringer Ingelheim Investigational Site
    Orthez, France
  • 1235.20.107E Boehringer Ingelheim Investigational Site
    Orthez, France
  • 1235.20.107G Boehringer Ingelheim Investigational Site
    Orthez, France
  • 1235.20.109A Boehringer Ingelheim Investigational Site
    Rosiers d'Egletons, France
  • 1235.20.109F Boehringer Ingelheim Investigational Site
    Saint Aulaire, France
  • 1235.20.104A Boehringer Ingelheim Investigational Site
    Saint Etienne, France
  • 1235.20.104D Boehringer Ingelheim Investigational Site
    Saint Etienne, France
  • 1235.20.107F Boehringer Ingelheim Investigational Site
    Salies de Bearn, France
  • 1235.20.105A Boehringer Ingelheim Investigational Site
    Toulon, France
  • 1235.20.105D Boehringer Ingelheim Investigational Site
    Toulon, France
  • 1235.20.152 Boehringer Ingelheim Investigational Site
    Budapest, Hungary
  • 1235.20.156 Boehringer Ingelheim Investigational Site
    Budapest, Hungary
  • 1235.20.158 Boehringer Ingelheim Investigational Site
    Budapest, Hungary
  • 1235.20.159 Boehringer Ingelheim Investigational Site
    Budapest, Hungary
  • 1235.20.161 Boehringer Ingelheim Investigational Site
    Budapest, Hungary
  • 1235.20.153 Boehringer Ingelheim Investigational Site
    Gyongyos, Hungary
  • 1235.20.154 Boehringer Ingelheim Investigational Site
    Miskolc, Hungary
  • 1235.20.157 Boehringer Ingelheim Investigational Site
    Miskolc, Hungary
  • 1235.20.155 Boehringer Ingelheim Investigational Site
    Mosonmagyarovar, Hungary
  • 1235.20.207 Boehringer Ingelheim Investigational Site
    Busan, Korea, Republic of
  • 1235.20.206 Boehringer Ingelheim Investigational Site
    Chunan, Korea, Republic of
  • 1235.20.205 Boehringer Ingelheim Investigational Site
    Koyang, Korea, Republic of
  • 1235.20.201 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.20.202 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.20.203 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.20.204 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1235.20.252 Boehringer Ingelheim Investigational Site
    Braila, Romania
  • 1235.20.259 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 1235.20.262 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 1235.20.254 Boehringer Ingelheim Investigational Site
    Iasi, Romania
  • 1235.20.261 Boehringer Ingelheim Investigational Site
    Oradea, Romania

Showing the first 100 of 137 sites across 11 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009 and a primary completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2009
First posted
Mar 12, 2009
Start
Mar 2009
Primary completionActual
Dec 2009
Results first posted
Jan 4, 2011
Last update
May 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00860262
First posted
Mar 12, 2009
Start date
Mar 2009
Primary completion
Dec 2009
Results posted
Jan 4, 2011
Last update
May 20, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion